BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TargeGen, Inc. Closes $40M Series 'D' Financing Round


7/12/2007 11:05:48 AM

SAN DIEGO, July 12 /PRNewswire/ -- TargeGen, Inc. has announced that the Company has successfully closed a $40M venture round of financing.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

New investors participating in the current round were Innovis Investments, VantagePoint Venture Partners and CTI Life Sciences Fund. Existing investors participating in the financing included Forward Ventures, Enterprise Partners, Chicago Growth Partners/William Blair Capital Partners, CDP Capital, BB BIOTECH, Hambrecht & Quist Capital Management, Pappas Ventures and other investors. In conjunction with the financing, Dr. Peter Bissinger of Innovis Investments has joined the TargeGen Board of Directors. "We are very pleased to be able to close another fully subscribed round of financing. We welcome the new investors and appreciate the continued support of our existing investors," said Peter G. Ulrich, President, CEO and Co-Founder of TargeGen.

TargeGen's most advanced drug candidate is TG100801, a topical (eye drop), multi-target kinase inhibitor for the treatment of macular degeneration, diabetic macular edema and diabetic retinopathy. TargeGen expects to initiate Phase II clinical trials in macular degeneration patients with TG100801 by the end of this month. Additionally, TargeGen is developing TG101348, a Jak2 inhibitor, for the treatment of myeloproliferative diseases including myelofibrosis with myeloid metaplasia, polycythemia vera and essential thrombocytopenia. Patient trials with TG101348 are planned for early 2008. TargeGen has additional compounds targeting inflammatory and ocular diseases in pre-clinical development.

About TargeGen, Inc.

TargeGen, Inc. is a privately held, vascular biology-focused biopharmaceutical company based in San Diego, CA. The Company primarily focuses on the development of small molecule kinase inhibitors that act on vascular permeability, vascular proliferation and inflammatory mechanisms common to many major human diseases.

Photo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comTargeGen, Inc.

CONTACT: Peter G. Ulrich, President & CEO of TargeGen, Inc.,+1-858-678-0760, fax, +1-858-678-0762, info@targegen.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES